Find NHLBI Clinical Trials

Search selected NHLBI-supported clinical trials and observational studies by condition, location, or age group. You can also view the complete list of NHLBI-funded studies at ClinicalTrials.gov.

FILTER BY KEYWORD

Showing 1 - 3 out of 3 results
Recruiting
The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.
Adult, Older Adult
Recruiting
Minnesota
Are you a Minnesota resident with hypertrophic cardiomyopathy? This study aims to find out how common it is for people with hypertrophic cardiomyopathy to also have sleep apnea. Hypertrophic cardiomyopathy is a disease that causes the heart muscle to thicken. Participants will also wear a heart rhythm monitor to help researchers learn whether sleep apnea is linked to arrhythmia. The study seeks healthy volunteers as well as participants in the Hypertrophic Cardiomyopathy Registry. To participate in this study, you must not have had a catheter ablation procedure to treat atrial fibrillation, had surgery to replace your heart valves, or been treated for sleep apnea. The study is located in Rochester, Minnesota.
Adult, Older Adult
Accepting Healthy Volunteers
Recruiting
Have you been diagnosed with peripartum cardiomyopathy and are within 5 months of your due date? This study is evaluating the effectiveness of a medicine called bromocriptine to treat peripartum cardiomyopathy, or weakness of the heart muscle that occurs during or shortly after pregnancy. To participate in this study, you must be at least 18 years old, diagnosed with peripartum cardiomyopathy, and within 5 months of your delivery date. This study takes place in Pittsburgh, Pennsylvania.
Adult, Older Adult
Female